Decision: Favourable
Study Title:
A Phase 3, Randomized, Multicentre, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Participants with Light Chain (AL) Amyloidosis
NREC Code:
22-NREC-CT-129
Decision:
Favourable
Meeting Date:
27/07/2022
Study Type:
CT application
Principal Investigator:
Dr John Quinn
PI Institution:
Beaumont Hospital
Sponsor:
Prothena Biosciences Limited